Exagen reports record Q2 revenue, lifts 2026 guidance

Exagen Inc. increased full-year revenue guidance to $72M-$75M after reporting a record $19.9M in Q2 revenue, driven by higher test volumes and ASPs. The diagnostics company narrowed its adjusted EBITDA loss to $0.1 million, signaling progress towards sustainable profitability.